Spots Global Cancer Trial Database for Apatinib for Advanced Non-squamous Head and Neck Cancer

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Apatinib for Advanced Non-squamous Head and Neck Cancer

Official Title: The Clinical Study of Apatinib for Patients With Advanced Non-squamous Head and Neck Cancer

Study ID: NCT02989259

Conditions

Head and Neck Neoplasms

Interventions

Apatinib

Study Description

Brief Summary: In this study, the investigators try to evaluate the efficacy and safety of apatinib in advanced non-squamous head and neck cancer and to validate the correlative biomarkers.

Detailed Description: There is no standard therapy for patients with advanced (unresectable, locally advanced, recurrent or metastatic) non-squamous head and neck cancer. Apatinib is a novel vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor, which has been approved for the treatment of patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy. Vascular endothelial growth factor is highly expressed in non-squamous head and neck cancer and its expression correlates with stage, tumour size, vascular invasion, recurrence and metastasis. In this study, the investigators try to evaluate the efficacy and safety of apatinib in advanced non-squamous head and neck cancer and to validate the correlative biomarkers.